Business Description
Universe Pharmaceuticals Inc
ISIN : KYG9442G1120
Total Employee Number:
216Description
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.63 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -3.17 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.61 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -82 | |||||
3-Year EBITDA Growth Rate | 81.8 | |||||
3-Year EPS without NRI Growth Rate | 82.6 | |||||
3-Year FCF Growth Rate | 62.9 | |||||
3-Year Book Growth Rate | -76.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.71 | |||||
9-Day RSI | 36.23 | |||||
14-Day RSI | 42.87 | |||||
3-1 Month Momentum % | -10.06 | |||||
6-1 Month Momentum % | -27.52 | |||||
12-1 Month Momentum % | -19.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.07 | |||||
Quick Ratio | 3.9 | |||||
Cash Ratio | 2.55 | |||||
Days Inventory | 78.91 | |||||
Days Sales Outstanding | 245.83 | |||||
Days Payable | 147.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -354.4 | |||||
Shareholder Yield % | -739.64 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 35.29 | |||||
Operating Margin % | -16.33 | |||||
Net Margin % | -20.56 | |||||
EBITDA Margin % | -16.36 | |||||
FCF Margin % | -30.24 | |||||
OCF Margin % | -28.29 | |||||
ROE % | -7.02 | |||||
ROA % | -5.05 | |||||
ROIC % | -11.34 | |||||
3-Year ROIIC % | 1298.42 | |||||
ROC (Joel Greenblatt) % | -16.29 | |||||
ROCE % | -6.41 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.08 | |||||
PB Ratio | 0.03 | |||||
Price-to-Tangible-Book | 0.03 | |||||
EV-to-EBIT | 6.44 | |||||
EV-to-EBITDA | 7.58 | |||||
EV-to-Revenue | -1.24 | |||||
EV-to-FCF | 4.1 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Projected-FCF | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.05 | |||||
| Price-to-Net-Cash | 0.09 | |||||
Earnings Yield (Greenblatt) % | 15.53 | |||||
FCF Yield % | -245.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UPC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Universe Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17.859 | ||
| EPS (TTM) ($) | -8.06 | ||
| Beta | 1.244 | ||
| 3-Year Sharpe Ratio | -0.32 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 92.52 | ||
| 14-Day RSI | 42.87 | ||
| 14-Day ATR ($) | 1.068264 | ||
| 20-Day SMA ($) | 5.22925 | ||
| 12-1 Month Momentum % | -19.4 | ||
| 52-Week Range ($) | 2 - 17.96 | ||
| Shares Outstanding (Mil) | 0.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Universe Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Universe Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-08-26 10:00 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | 3.79 (-5.25%) | ||
| Annual report for 2025 | 2026-01-29 | 4.30 (+4.88%) | ||
| General meeting for 2025 | 2025-08-26 10:00 | 3.56 (+2.01%) | ||
| Annual report for 2024 | 2025-04-29 | 5.95 (+27.14%) | ||
| 0.025:1 Stock Split | 2025-03-24 | 3.52 (+6.14%) | ||
| 0.0666667:1 Stock Split | 2024-11-18 | 84.42 (-13.42%) | ||
| Second quarter earnings results for 2024 | 2024-09-20 | 204.72 (-3.89%) | ||
| 0.166667:1 Stock Split | 2023-07-28 | 1,331.64 (+6.42%) |
Show
Entries
Universe Pharmaceuticals Inc Frequently Asked Questions
What is Universe Pharmaceuticals Inc(UPC)'s stock price today?
The current price of UPC is $3.39. The 52 week high of UPC is $17.96 and 52 week low is $2.00.
When is next earnings date of Universe Pharmaceuticals Inc(UPC)?
The next earnings date of Universe Pharmaceuticals Inc(UPC) is 2027-01-24 Est..
Does Universe Pharmaceuticals Inc(UPC) pay dividends? If so, how much?
Universe Pharmaceuticals Inc(UPC) does not pay dividend.
Guru Commentaries on NAS:UPC
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Universe Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers